Daicel Corporation (TYO:4202)

Market Cap	346.19B +10.5%
Revenue (ttm)	579.63B -1.2%
Net Income	10.18B -79.4%
EPS	38.74 -78.6%
Shares Out	255.39M
PE Ratio	34.99
Forward PE	9.99
Dividend	60.00 (4.62%)
Ex-Dividend Date	Mar 30, 2026

Volume	2,230,400
Open	1,310.00
Previous Close	1,299.00
Day's Range	1,302.00 - 1,363.00
52-Week Range	1,112.50 - 1,658.00
Beta	0.54
Analysts	Hold
Price Target	1,437.50 (+6.05%)
Earnings Date	Jul 31, 2026

About Daicel

Daicel Corporation engages in the materials, medical/healthcare, smart, safety, and engineering plastics businesses in Japan and internationally. The company offers medical/healthcare products, including BELLOCEA S7, a spherical cellulose acetate particle; FLAVOCELL S-Equol; Urolithin A; polyglycerols; konjac ceramide; excipients for foods; chiral columns and reagents; and Actranza lab, as well as separation and analytical services. It also provides performance films, solvents for electronic materials, cycloaliphatic epoxies, polymers for photo...

• Industry: Specialty Chemicals
• Sector: Materials
• Founded: 1919
• Employees: 11,178
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4202

Financial Performance

In fiscal year 2026, Daicel's revenue was 579.63 billion, a decrease of -1.18% compared to the previous year's 586.53 billion. Earnings were 10.18 billion, a decrease of -79.43%.

Analyst Summary

According to 8 analysts, the average rating for 4202 stock is "Hold." The 12-month stock price target is ¥1,438, which is an increase of 6.05% from the latest price.

Price Target

¥1,438

(6.05% upside)

Analyst Consensus: Hold

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jun 15, 2026

Data Sources Report a data error